Michael Unterhalt, MD, on Mantle Cell Lymphoma: Long-Term Follow-up Results

2017 ASH Annual Meeting
Tweet this page

Michael Unterhalt, MD, of the University Hospital Grosshadern, discusses study findings on rituximab maintenance after first-line immunochemotherapy among older patients who are not candidates for autologous stem cell transplantation (Abstract 153).

Advertisement

Advertisement



Advertisement